Atypical symptoms in geriatric depression

Abstract

patients receiving 1 mg/day of risperidone fhan placebo. On the Clinical Global Impressions scale, a rating of much or very much improved was received by 26% of placebo patients and 30%, 45%, and 40% of the risperidone patients. Differences were significant between placebo and risperidone at 1.0 mg/day (p<O.OOl) and 2.0 mg/day (J~0.05). It is concluded that, in elderly patients with dementia and psychotic symptoms at baseline, risperidone was efficacious in treating psychosis and behavioral disturbances.